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SUMMARY
Human pluripotent stem cell-derived vascular smooth muscle cells (hPSC-VSMCs) are of great value for disease modeling, drug screening,
cell therapies, and tissue engineering. However, producing a high quantity of hPSC-VSMCs with current cell culture technologies remains
very challenging. Here, we report a scalable method for manufacturing hPSC-VSMCs in alginate hydrogel microtubes (i.e., AlgTubes),
which protect cells from hydrodynamic stresses and limit cell mass to <400 mm to ensure efficient mass transport. The tubes provide cells
a friendly microenvironment, leading to extremely high culture efficiency. We have shown that hPSC-VSMCs can be generated in 10 days
with high viability, high purity, and high yield (5.0 3 108 cells/mL). Phenotype and gene expression showed that VSMCs made in
AlgTubes and VSMCs made in 2D cultures were similar overall. However, AlgTube-VSMCs had higher expression of genes related to vasculature development and angiogenesis, and 2D-VSMCs had higher expression of genes related to cell death and biosynthetic processes.

INTRODUCTION
Vascular smooth muscle cells (VSMCs) are critical in the
development, function, and maintenance of blood vessels
(Carmeliet, 2000; Owens et al., 2004). VSMC dysfunction
can lead to a variety of diseases (Melanie et al., 2014; Porter
and Riches, 2013). VSMCs are important, and required in
large numbers for drug discovery and disease modeling
(Biel et al., 2015; Ge et al., 2012; Granata et al., 2017; Ji
et al., 2017; Kinnear et al., 2013a; Liu et al., 2011; Zhang
et al., 2014, 2011), tissue engineering (Ferreira et al., 2007;
Hibino et al., 2012; Karamariti et al., 2013; Levenberg,
2005; Park et al., 2010; Patsch et al., 2015; Wang et al.,
2016, 2014; Yoo et al., 2013), and cell therapies (Cheung
et al., 2012; Emilio et al., 2006; Hattan et al., 2004; Hong
et al., 2017; Li et al., 1999; Matsubayashi et al., 2003; Staudacher et al., 2006; Wang et al., 2016; Wanjare et al., 2013;
Ye et al., 2014). It is, however, a great challenge to retrieve
enough primary VSMCs from fetal or adult human tissues
(Cheung et al., 2014; Owens et al., 2004; Poh et al., 2005).
This difficulty could potentially be resolved by using
human pluripotent stem cells (hPSCs), including human
embryonic stem cells (hESCs) (Thomson et al., 1998) and
induced pluripotent stem cells (iPSCs) (Levenberg et al.,
2007; Takahashi et al., 2007; Yu et al., 2007). Large numbers

of hPSCs can be grown due to their ability to continually
proliferate in vitro. They are also capable of differentiating
into all somatic cell types (Chen et al., 2011; Lei and
Schaffer, 2013). Also, patient-specific derived iPSCs retain
the patient’s genetic information, which is important in
modeling many human diseases (Okita et al., 2011; Takahashi et al., 2007). This also allows these cells to produce little
or no immune response in the patient (Lalit et al., 2014).
Protocols for effectively differentiating hPSCs into VSMCs
have been developed in the past decade, through either
embryoid bodies (Biel et al., 2015; Ge et al., 2012; Kinnear
et al., 2013b; Lee et al., 2010; Lin et al., 2012; Wang et al.,
2014; Yoo et al., 2013; Zhang et al., 2014) or monolayer
culture (Bajpai et al., 2012; Bao et al., 2015; Cheung et al.,
2012; Karamariti et al., 2013; Lian et al., 2014; Liu et al.,
2011; Melanie et al., 2014; Park et al., 2010; Patsch
et al., 2015; Taura et al., 2009; Wanjare et al., 2015, 2013;
Yang et al., 2016; Zhang et al., 2011). For instance,
researchers are able to generate developmental origin-specific VSMC subtypes from hPSCs, including neuroectodermal VSMCs, lateral plate mesodermal VSMCs, and paraxial
mesodermal VSMCs (Bernardo et al., 2011; Cheung et al.,
2012; Granata et al., 2017; Iyer et al., 2016; Raphel et al.,
2012; Sinha et al., 2004), or synthetic (Granata
et al., 2017; Wanjare et al., 2013, 2015) and contractile
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VSMCs from hPSCs (Bajpai et al., 2012; Eoh et al., 2017; Gerecht et al., 2010; Patsch et al., 2015; Pei et al., 2010; Vo et al.,
2010; Wanjare et al., 2015; Yang et al., 2016). Synthetic
VSMCs are at a proliferative state, while contractile VSMCs
are at a quiescent yet functional state (Ayoubi et al., 2017).
Contractile VSMCs are critical for maintaining proper blood
flow and normal vessel tone (Alexander and Owens, 2012).
The synthetic phenotype has an unfavorable role in human
blood vessels, and is associated with conditions such as
atherosclerosis and hypertension (Lacolley et al., 2012;
Louis and Zahradka, 2010). Under certain conditions,
VSMCs can actually switch between the two phenotypes
(Mark and Christine, 2012). Patsch and colleagues have
recently demonstrated a protocol that can differentiate
hPSCs into mesoderm and then VSMCs, using a two-dimensional (2D) culture system, in just 6 days (Patsch et al., 2015).
Their protocol is efficient and simple, making it incredibly
useful for making VSMCs for a range of biomedical procedures, especially for clinical applications.
Although it is possible to readily make hPSC-VSMCs on a
small scale in basic research laboratories, it is still very difficult to produce hPSC-VSMCs at the larger quantities
needed by many biomedical applications. The current 2D
methods for culturing cells (e.g., growing cells on 2D surfaces like plates or flasks) generally produce such a low
cell yield that they are typically utilized when small
numbers of cells are needed (e.g., <1010) (Jenkins and Farid,
2015; Kropp et al., 2017). Three-dimensional suspension
culturing methods (e.g., culturing cells in agitated medium
in stirred-tank bioreactors) are being studied to scale up the
cell production, and this technique has been shown to
have encouraging results. However, 3D culture systems
do have significant limitations (Jenkins and Farid, 2015;
Kropp et al., 2017; Lei et al., 2014; Lei and Schaffer, 2013;
Serra et al., 2012; Steiner et al., 2010; Wurm, 2004). hPSCs
have both strong cell-to-cell and strong cell-to-matrix adhesions. They frequently form large cellular agglomerates
by aggregating in 3D suspension (Kropp et al., 2017). Due
to the fact that the diffusion limit in human tissue is in
the range of 300–400 mm, the mass transport in cellular agglomerates larger than 400 mm (in diameter) becomes
limited. This restriction in mass transport can increase
apoptosis, cause uncontrolled differentiation, and slow
cell growth (Kropp et al., 2017). Mass transport and medium mixing can be enhanced, and cell agglomeration
can be reduced by simply agitating the culture. While agitation has its benefits, it can also generate significant, negative, and uncontrollable hydrodynamic stresses (e.g., shear
force), which can greatly increase cell death (Fridley et al.,
2012; Kinney et al., 2011; Kropp et al., 2017). This can
result in decreased cell viability leading to slower growth
and lower volumetric yield, all of which are common in
3D suspension culturing (Lei and Schaffer, 2013).

To address the challenge, we previously developed a scalable and high-yield cell culture method for expanding
hPSCs and other human cells (Li et al., 2018a, 2018b; Lin
et al., 2018a, 2018b). With this method, cells are processed
into microscale alginate hydrogel tubes (AlgTubes) that are
suspended in the cell culture medium. These tubes significantly improved the hPSC culture efficiency and consistency. Under optimized culture conditions, hPSCs could
be cultured in these hydrogel tubes long term (e.g., >10 passages, >50 days) with high cell viability, high purity (>95%
pluripotency markers, e.g., OCT4, NANOG, ALP, and
SSEA4), and high yield (5.0 3 108 cells/mL of microspace). However, whether hPSCs can be efficiently differentiated into VSMCs in the alginate hydrogel tubes and if
alginate hydrogel tubes could affect the phenotypes of
produced VSMCs have not been studied. In this paper, we
systematically address these questions. Consequently, we
have developed a highly efficient and scalable method for
producing hPSC-VSMCs with high volumetric yield, high
viability, and high purity.

RESULTS
Processing Cells into Alginate Hydrogel Tubes
A microextruder was used to process hPSCs into AlgTubes
according to our previous study (Li et al., 2018a) (Figures
1A–1C). In the hydrogel tubes, single hPSCs first associated
to form small clusters that subsequently grew into spheroids that eventually filled the tube (Figure 1D). Very few
dead cells were detected during the culture (Figure 1E). Immunostaining and flow cytometry analyses revealed >95%
cells positive for the pluripotency markers OCT4, NANOG,
ALP, and SSEA4 (Figure 1F). When seeded at 1.0 3 106
cells/mL, H9s, Fib-iPSCs (iPSCs reprogrammed from dermal
fibroblasts), and MSC-iPSCs (iPSCs reprogrammed from
bone marrow mesenchymal stem cells) expanded 30-,
150-, and 480-fold to yield 30, 150, and 480 3 106
cells/mL of microspace on days 5, 7, and 9, respectively
(Figures 1G and 1H). For comparison, typically 2–3 million
cells can be generated in one well of a six-well plate. To
generate massive numbers of hPSCs, the day 9 cell masses
can be released by dissolving the hydrogel tubes with
0.5 mM EDTA solution (5 min at room temperature), and
dissociated into single cells with Accutase and processed
into new hydrogel tubes for a second round of expansion.
Once the targeted cell number is reached, hPSCs can be
differentiated into VSMCs within 5 days.
Making hPSC-VSMCs in Alginate Hydrogel Tubes
We first checked and confirmed that our starting cells,
including H9 hESCs, Fib-iPSCs, and MSC-iPSCs (Park
et al., 2008), were high-quality pluripotent stem cells
Stem Cell Reports j Vol. 12 j 84–97 j January 8, 2019 85

Figure 1. Culturing hPSCs in Alginate Hydrogel Tubes (AlgTubes)
(A–C) Overview of alginate hydrogel culture system. (A) A microextruder is built for processing cells into microscale alginate hydrogel
tubes. (B) A cell suspension and an alginate solution are pumped into the central channel and side channel of the microextruder,
respectively, to form coaxial core-shell flows that are extruded through the nozzle into a CaCl2 buffer. (C) The hydrogel tubes protect cells
from hydrodynamic stresses and confine the cell mass to <400 mm (in radial diameter) to ensure efficient mass transport. The tubes provide
uniform and cell-friendly microspaces that allow cells to interact with one another and expand.
(D) Phase images of H9 hESCs in hydrogel tubes on days 0, 1, 5, 7, and 9. Scale bar, 200 mm.
(E) Live/dead cell staining of day 9 cells in hydrogel tubes. Scale bar, 200 mm.
(F) Immunostaining of day 9 H9 hESCs for pluripotency markers OCT4, NANOG, SSEA4, and ALP. Scale bar, 200 mm.
(G and H) Seeded at 1.0 3 106 cells/mL, H9s, Fib-iPSCs, and MSC-iPSCs expanded (G) 30-, 150-, and 480-fold to yield (H) 30, 150, and
480 3 106 cells/mL of microspace on days 5, 7, and 9. Data are represented as mean ± SD (n = 3).

(Figure S1). Patsch et al. reported an efficient protocol that
could differentiate hPSCs into VSMCs in 6 days in 2D
culturing (Patsch et al., 2015). This protocol is simple and
quick, and thus is very appealing for making VSMCs for
various biomedical applications, especially for clinical
applications. We successfully repeated this protocol (Figure S2). We termed VSMCs made in 2D culturing as
2D-VSMCs.
We then studied whether the protocol could be used to
generate VSMCs in alginate hydrogel tubes (Figure 2A).
Single hPSCs were processed into the hydrogel tubes
86 Stem Cell Reports j Vol. 12 j 84–97 j January 8, 2019

and expanded for 5 days to generate small spheroids. On
day 5, the differentiation medium was applied. Cells were
harvested for analysis on day 10 (Figure 2B). Live/dead
staining and cell viability analysis showed very high cell
viability on day 10 (Figures 2C and 2D). About 5.0 3 108
cells/mL of microspace were produced on day 10 (Figure 2E). Immunostaining and confocal imaging showed
that the majority of the produced cells were positive for
VSMC markers SM22A and a-SMA (Figures 2F and 2G).
VSMCs were uniformly distributed, and no cysts were
found in the cell mass, indicating no or little cell death

Figure 2. Differentiating H9 hESCs into VSMCs in Alginate Hydrogel Tubes
(A) The VSMC differentiation protocol.
(B) Phase images of day 0, 5, 8, and 10 cells. Scale bar, 200 mm.
(C and D) (C) Live/dead staining and (D) cell viability of day 10 cells. Data are represented as mean ± SD (n = 5). Scale bar, 200 mm.
(E) Volumetric yield on day 10. Data are represented as mean ± SD (n = 5).
(legend continued on next page)
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during the differentiation. Flow cytometry analysis found
84.1% of the cells were SM22A+ and a-SMA+ (Figure 2H).
Scanning electron microscopy (SEM) showed there was
no adhesion between AlgTube-VSMCs and alginate hydrogel tubes (Figure 2I). When the day 10 cells were released
from the tubes and dissociated into single cells and plated
on Matrigel-coated plates at high density, they formed a
monolayer with tight cell-cell interactions (Figure 2J).
The majority of the cells were SM22A+ and a-SMA+ VSMCs
(Figure 2K), 10% of cells were VE-CADHERIN+ endothelial cells (Figures 2L and 2N), and no OCT4+ and NANOG+
undifferentiated hPSCs were detected (Figures 2M and 2N).
H9s, Fib-iPSCs, and MSC-iPSCs had similar outcomes (Figures S3 and S4). We found that the differentiation efficiencies in 2D culturing and in hydrogel tubes were very
close. We termed VSMCs made in hydrogel tubes as AlgTube-VSMCs.
To study whether the diameter of the hydrogel tubes
affected the differentiation efficiency, we differentiated
hPSCs into VSMCs in hydrogel tubes with a diameter of
120, 250, or 330 mm. The diameter of the hydrogel tubes
can be precisely controlled through adjusting the nozzle
diameter of the microextruder (Li et al., 2018a). hPSCs
were successfully differentiated into VSMCs in all three
tubes with similar cell viability, differentiation efficiency,
and yield (Figures S5A and S5B). Quantitative RT-PCR analysis revealed that cells in 250 mm hydrogel tubes had significantly higher expression for some important VSMC genes,
including a-SMA, SM22A, CALPONIN, VEGFA, FN,
COL4A5, and COL4A6 (Figures S5C–S5E). We thus decided
to use 250 mm hydrogel tubes for the rest of the studies.
Properties of hPSC-VSMCs Made in Alginate Hydrogel
Tubes and 2D Culture
Our culture system provides cells a 3D microenvironment.
Recent research on organoids demonstrates that 3D microenvironments promote the formation of structured tissues
during the differentiation of pluripotent stem cells (Hattori, 2014; Jo et al., 2016; Takahashi et al., 2018). Therefore,
we asked if AlgTube-VSMCs and 2D-VSMCs were similar
in phenotypes, functions, and gene expression. VSMCs
were replated in six-well plates for phenotype assays
after 5 days differentiation. The fibronectin deposition
assay showed that AlgTube-VSMCs and 2D-VSMCs had
similar fibronectin production in response to transforming
growth factor b (TGF-b) stimulation (Figures 3A–3C). When

co-cultured with human umbilical vein endothelial cells
(HUVECs), both types of VSMCs attached to the tubular
network formed by the HUVECs (Figure 3D). AlgTubeVSMCs had more contraction in response to carbachol
treatment than 2D-VSMCs in vitro (Figures 3E–3G),
although the carbachol-induced intracellular calcium
levels were similar (Figure 3H). When subcutaneously injected with HUVECs into immunodeficient mice for
2 weeks, both AlgTube-VSMCs and 2D-VSMCs contributed
to the newly formed blood vessels (Figure 3I). The numbers
of VSMCs attached to the vessels were similar (Figure 3J).
Similar results were found for Fib-iPSC-derived VSMCs (Figures S6A–S6G). These results show that AlgTube-VSMCs
and 2D-VSMCs are similar and both have the typical
VSMC phenotypes.
Transcriptome Analysis of AlgTube-VSMCs and 2DVSMCs
We sequenced the mRNAs of AlgTube-VSMCs and 2DVSMCs derived from H9s and undifferentiated H9s (three
biological replicates for each) to analyze their global gene
expression. Hierarchical clustering analysis showed that
AlgTube-VSMCs and 2D-VSMCs clustered closely (Figure 4A). The genome-wide gene expression profile correlation coefficients between the AlgTube-VSMCs and the
2D-VSMCs were >0.81, indicating that they had similar
global gene expressions (Figure 4B). However, the separation of 2D-VSMCs and AlgTube-VSMCs in PC2 of the
principal component analysis (PCA) indicated these cells
had some differences in gene expression (Figure 4C),
which drove us to perform differential gene expression
analysis.
Differential gene expression analysis identified 807
genes significantly upregulated in AlgTube-VSMCs, and
719 genes significantly upregulated in 2D-VSMCs (Table
S3). Gene Ontology (GO) terms upregulated in AlgTubeVSMCs were mainly related to vasculature development
and angiogenesis (Figure 4D). GO terms upregulated in
2D-VSMCs were related to apoptotic process and biosynthesis (Figure 4E). Detailed gene expression analysis using
the RNA sequencing (RNA-seq) data showed that AlgTubeVSMCs and 2D-VSMCs had significant differences in the
expression of genes related to extracellular matrices,
such as those for COLLAGENS, LAMININS, INTEGRINS,
and PROTEASES (Figures S7A–S7E); VSMC secreted factors
(Figure S7F); EPHRIN signaling (Figure S7G); angiogenesis

(F–H) (F) Immunostaining and (H) flow cytometry analysis of day 10 cells for VSMC markers SM22A and a-SMA. (G) Confocal microscope
images of four slices of one fibrous cell mass stained with VSMC markers a-SMA and SM22A. Scale bars, 100 and 10 mm, respectively.
(I) SEM image of hPSC-VSMCs in hydrogel tubes on day 10 (green arrow, cells; red arrows, hydrogel tubes). Scale bar, 10 mm.
(J–N) The day 10 cell masses were dissociated into single cells and plated on 2D surface overnight. (J) Phase image and (K) immunostaining showed the majority of the cells were SM22A+ and a-SMA+ VSMCs, and (L and N) 10% were VE-CADHERIN+ endothelial cells, but
(M and N) there were no OCT4+/NANOG+ undifferentiated hPSCs. Data are represented as mean ± SD (n = 3). Scale bar, 50 mm.
88 Stem Cell Reports j Vol. 12 j 84–97 j January 8, 2019

Figure 3. Properties of hPSC-VSMCs Made in 2D Culture (2D-VSMCs) and Alginate Hydrogel Tubes (AlgTube-VSMCs)
(A–C) Immunostaining of fibronectin production of (A) 2D-VSMCs and (B) AlgTube-VSMCs after 24 hr of 2.5 ng/mL TGF-b treatment.
(C) Quantification of produced fibronectin. Data are represented as mean ± SD (n = 5). Scale bar, 50 mm.
(D) Co-culture of VSMCs and HUVECs. Scale bar, 50 mm.
(E–G) (E) Phase images, (F) surface area, and (G) percentage change in cell surface area of 2D-VSMCs and AlgTube-VSMCs in response to
carbachol treatment. Data are represented as mean ± SD. **p < 0.01, ***p < 0.001. Scale bar, 50 mm.
(H) The relative fluorescence units (DRFU) of Fluo-4-loaded VSMCs over 10 min after adding carbachol. Data are represented as mean ± SD
(n = 3).
(I and J) When VSMCs and HUVECs were co-transplanted subcutaneously, both 2D-VSMCs and AlgTube-VSMCs (I) formed nice vascular
structures with (J) similar numbers of VSMCs attached to the vessels. Scale bar, 50 mm.

(Figure S7H); vasculature development (Figure S7I);
NOTCH signaling (Figure S7J); cell differentiation (Figure S7K); and cell cycle and proliferation (Figure S7L).
These results show that the 3D microenvironment of

AlgTubes promoted vasculature development during the
differentiation.
We also briefly compared the global gene expression
profiles of AlgTube-VSMCs and 2D-VSMCs with those of
Stem Cell Reports j Vol. 12 j 84–97 j January 8, 2019 89

Figure 4. Whole Transcriptome Analysis
of AlgTube-VSMCs and 2D-VSMCs Derived
from H9 hESCs
(A) Global heatmap of expressed genes.
(B) The scatterplot in log scale of global
gene expression between AlgTube-VSMCs
and 2D-VSMCs.
(C) Principal component analysis of AlgTubeVSMCs, 2D-VSMCs, and H9s. Three biological
replicates were used for each sample.
(D and E) Top 20 GO terms of upregulated
genes in (D) AlgTube-VSMCs and (E) 2DVSMCs.

primary human aortic smooth muscle cells (HASMCs). The
RNA-seq data of primary HASMCs were obtained from the
literature (Pan et al., 2018). It should be noted that these
HASMCs had been cultured in 2D plates in serum-containing medium before RNA sequencing and the 2D culturing
may have altered their global gene expression profiles.
The genome-wide gene expression profile correlation coefficients were 0.74 between AlgTube-VSMCs and HASMCs,
and were 0.63 between 2D-VSMCs and HASMCs (Figures
S7M and S7N). These results indicate that AlgTube-VSMCs
are closer to HASMCs than 2D-VSMCs. However, both
AlgTube-VSMCs and 2D-VSMCs have differences from
HASMCs in terms of global gene expression. It is likely
due to the fact that VSMCs derived from hPSCs are not as
mature as primary VSMCs. Further studies to identify the
differences in gene expression, phenotypes, and functions
between hPSC-VSMCs and primary VSMCs (especially
those that have not been cultured in vitro) should be
done in the future.
90 Stem Cell Reports j Vol. 12 j 84–97 j January 8, 2019

Using quantitative RT-PCR analysis, we found that both
AlgTube-VSMCs and 2D-VSMCs had very low expression
levels of the pluripotency markers OCT4 and NANOG (Figure 5A). 2D-VSMCs had higher expression of the synthetic
VSMC genes such as a-SMA, SM22A, and CALPONIN (Figure 5B), and AlgTube-VSMCs had higher expression of the
mature and contractile VSMC markers such as SMOOTHELIN
(SMTN), MYOSIN HEAVY CHAIN 11 (MYH11), and ELASTIN
(Figure 5C). These results indicate that 2D-VSMCs are closer
to a synthetic phenotype and AlgTube-VSMCs are closer to a
contractile phenotype. AlgTube-VSMCs had enhanced
expression of extracellular matrix (ECM) genes (FN,
COL4A6, and MMP9) (Figure 5D), growth factors (VEGFA
and VEGFC) (Figure 5E), and other genes related to angiogenesis (PECAM1, ANGPT2, NOTCH4, and DLL4) compared
with 2D-VSMCs (Figure 5F). Using Ki-67 immunostaining
and flow cytometry analysis, we found more cells were
proliferating in 2D-VSMCs (Figures 5G and 5H). These analyses well supported the RNA-seq data.

Figure 5. Gene Expression and Cell Proliferation Comparison of 2D-VSMCs and AlgTube-VSMCs
(A–F) qRT-PCR analyses of 2D-VSMCs, AlgTube-VSMCs, and H9 hESCs for (A) pluripotency markers OCT4 and NANOG, (B) synthetic VSMC
markers a-SMA, SM22A, and CALPONIN, (C) contractile VSMC markers SMTN, MYH11, and ELASTIN, (D) ECM genes FN, COL4A, and MMP9, (E)
growth factors VEGFA and VEGFC, and (F) other genes related to angiogenesis, PECAM1, ANGPT2, NOTCH4, and DLL4. Data are represented as
mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001.
(G and H) Immunostaining and flow cytometry of Ki67 showed that (G) 2D-VSMCs had more proliferating cells than (H) AlgTube-VSMCs.
Scale bar, 50 mm.
Scalable Manufacturing of hPSC-VSMCs in a
Bioreactor
The above studies were done using a small volume (e.g.,
<100 mL) of AlgTubes suspended in a six-well plate. We
asked if AlgTubes could be suspended in a scalable biore-

actor (Li et al., 2018a) for making hPSC-VSMCs at various
scales (Figures 6A and 6B). Cells were expanded for 5 days
and differentiated for 5 days in the bioreactor (Figure 6C).
On day 10, hydrogel tubes were dissolved with EDTA and
cells were harvested. Phase image and live/dead cell
Stem Cell Reports j Vol. 12 j 84–97 j January 8, 2019 91

Figure 6. Making hPSC-VSMCs in a Bioreactor
(A) The bioreactor.
(B) Illustration of medium exchange.
(C) Day 10 cells in the bioreactor.
(D–G) (D) Phase, (E) live/dead cell staining, (F) immunostaining, and (G) flow cytometry analysis of day 10 cells from the bioreactor. Scale
bars, 200, 50, and 20 mm, respectively.
(H and I) (H) Phase and (I) surface area of AlgTube-VSMCs made using the bioreactor in response to carbachol treatment. Scale bar, 50 mm.
Data are represented as mean ± SD (n = 3). ***p < 0.001.
(J) The relative fluorescence units (DRFU) of Fluo-4-loaded VSMCs made with the bioreactor over 10 min after adding carbachol. Data are
represented as mean ± SD (n = 3).
(K) When VSMCs made with the bioreactor and HUVECs were co-transplanted subcutaneously, they formed nice vascular structures. Scale
bar, 50 mm.
(L) qRT-PCR analysis showed that AlgTube-VSMCs made using the bioreactor had similar expression levels of VSMC markers compared with
AlgTube-VSMCs made using tissue culture plates (non-bioreactor). Data are represented as mean ± SD (n = 3).
staining showed that the majority of cells were live (Figures
6D and 6E). Flow cytometer analysis and immunostaining
showed that 85.7% of the produced cells were VSMCs
92 Stem Cell Reports j Vol. 12 j 84–97 j January 8, 2019

(Figures 6F and 6G). VSMCs produced in the bioreactor
(bioreactor-VSMCs) contracted in response to carbachol
treatment in vitro (Figures 6H and 6I). Calcium imaging

revealed that carbachol induced similar levels of intracellular calcium between bioreactor-VSMCs and non-bioreactor-VSMCs (i.e., AlgTube-VSMCs made using tissue
culture plates) (Figure 6J). A transplantation study showed
that bioreactor-VSMCs contributed to blood vessel formation in vivo (Figure 6K). Quantitative RT-PCR analysis
showed that bioreactor-VSMCs had similar expression
levels of VSMC markers compared with non-bioreactorVSMCs (Figure 6L). We also showed that bioreactor-VSMCs
could be cultured for multiple passages without losing their
markers using the conventional 2D cultures (Figures S5F
and S5G). These results show that AlgTubes are appropriate
for preparing hPSC-VSMCs in a bioreactor. This prototype
bioreactor can be scaled up for large-scale production in
the future.

DISCUSSION
Generating enough hPSCs and their derivatives continues
to be challenging. At present, hPSC-VSMCs are primarily
made in 2D cultures (Patsch et al., 2015), which utilize
growth conditions that are considerably different from
the in vivo 3D microenvironment where cells reside
(Chen et al., 2014b, 2014a; Kraehenbuehl et al., 2011;
Thomson et al., 1998; Wong et al., 2010). Also, 2D
culturing is not conducive to preparing large-scale cultures
because it is labor, time, space, and reagent consuming
(Kropp et al., 2017). Three-dimensional suspension
culturing has successfully been shown to be an attractive
method to scale up the production of hPSCs and their derivatives (Fridley et al., 2012; Kinney et al., 2011; Kropp
et al., 2017). However, suspension growth of hPSCs continues to suffer from severe cellular agglomeration (Fridley
et al., 2012; Kinney et al., 2011; Kropp et al., 2017).
Applying agitation (stirring or shaking) to the culture can
reduce agglomeration and recover mass transport (Fridley
et al., 2012; Kinney et al., 2011; Kropp et al., 2017). However, agitation generates critical shear stress near the bioreactor wall and impeller tip that induces a large amount of
cell death, leading to low cell expansion and yield (Fridley
et al., 2012; Ismadi et al., 2014; Jenkins and Farid, 2015;
Kinney et al., 2011; Kropp et al., 2017; Lei et al., 2014;
Lei and Schaffer, 2013; Serra et al., 2012; Steiner et al.,
2010). Agitation also generates complicated hydrodynamic
conditions (e.g., the medium flow direction, velocity, shear
force, and chemical environment) that vary spatially and
temporally, and can be affected by a number of variables,
including the design of the bioreactor (e.g., impeller geometry, size and position, vessel geometry and size, and positions of probes for pH, temperature, oxygen), the viscosity
of the medium, and also the rate of agitation (Ismadi et al.,
2014; Kropp et al., 2017). The hydrodynamic conditions

are not very well understood yet, which makes them difficult to control (Fridley et al., 2012; Ismadi et al., 2014;
Kinney et al., 2011; Kropp et al., 2017). This lack of understanding and technological issues causes considerable
variability between culture batches, leading to further difficulty in scaling up culture size. For example, in recent 3D
culture studies to generate cardiomyocytes from hPSCs,
the cellular yield varied dramatically (from 40 million to
125 million cells) and the cellular purity varied from 28%
to 88% in six different batches (100 mL culture volume)
(Chen et al., 2015; Jara-avaca et al., 2014). When adjusting
the culture volume from 100 mL to 1000 mL, both the
efficiency of differentiation and the final product yield
were altered significantly, which led to the need for reoptimization (Chen et al., 2015; Jara-avaca et al., 2014). This
demonstrates the difficulty in scaling up further (e.g., hundreds of liters), due to the cost of optimizing multiple
factors in a large volume. To date, <10 L of hPSC culture
is the highest volume successfully produced (Kempf et al.,
2016; Kropp et al., 2017). As a result, hydrodynamic conditions, and the associated critical stresses in combination
with the uncontrolled cell aggregation, make it very challenging to utilize a 3D suspension culture system to
generate hPSCs and their derivatives at large scales.
The alginate hydrogel tubes could eliminate both the cell
agglomeration and the hydrodynamic stresses and their
related adverse effects (Figures 1A–1C). Consequently, the
culture efficiency (e.g., cell viability and yield) and consistency are significantly improved (Figures 1G and 1H). The
volumetric yield reached 5.0 3 108 cells/mL of microspace,
which is 250 times the current 3D suspension culturing.
This high yield has enormous impact on large-scale cell
production (Li et al., 2018a). Our calculations show that
the cells would need to undergo passaging 10 times,
32,753 L total bioreactor volume, and 45 days to produce
1.1 3 1013 hPSC-VSMCs using 1.0 3 108 hPSCs as starting
material. This production is technically and economically
not feasible. Using AlgTubes, the same cells can be made
using merely 320 L of hydrogel tubes, one passage, and
21 days. The reduction in culture volume, time, and
passaging makes the production technically and economically feasible.
Our research showed that the differentiation efficiencies
in 2D and AlgTubes were similar (Figures 2 and S2), indicating that the differentiation protocol developed by
Patsch (Patsch et al., 2015) using 2D cultures can be used
for 3D culture. Phenotype assays and genome-wide gene
expression analysis showed that AlgTube-VSMCs and 2DVSMCs were similar overall. Both of them had typical
VSMC phenotypes (Figure 3). Transplantation studies
showed that AlgTube-VSMCs and 2D-VSMCs contributed
to blood vessel formation similarly in vivo (Figures 3I and
3J). However, they do have some differences in global
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gene expression. AlgTube-VSMCs had higher expression of
genes related to vasculature development, angiogenesis,
and cell migration (Figure 4D). This agrees with recent
research on organoids, which shows that 3D microenvironments promote tissue formation (Hattori, 2014; Jo
et al., 2016; Takahashi et al., 2018). 2D-VSMCs are closer
to the synthetic phenotype. For instance, they had higher
proliferation (Figure 5G) and higher expression of the synthetic VSMC genes (Figure 5B). Two-dimensional culturing
on a stiff substrate induces cell proliferation, which is a
frequently observed phenomenon when culturing primary human cells (Chamley et al., 1977; Timraz et al.,
2015; Wazen et al., 2013). Both AlgTube-VSMCs and 2DVSMCs had some differences in global gene expression
from the primary HASMCs. If and how the differences in
global gene expression between the three types of VSMCs
affect their phenotypes and functions should be made
clear in the future using more sensitive assays and disease
models.
Conclusion
In summary, we have developed a scalable method for
manufacturing VSMCs from hPSCs with high viability,
high purity (>80%), and high yield (5.0 3 108 cells/mL
of microspace). The method will make VSMCs broadly
available and affordable for various applications.

EXPERIMENTAL PROCEDURES
RNA Sequencing and Data Analysis
Total RNA of day 6 VSMCs from 2D culture and day 10 VSMCs
from AlgTubes (note: both VSMCs were differentiated for 5 days)
was prepared with an RNeasy mini kit (Cat. No. 74,104;
QIAGEN) according to the manufacturer’s instructions. Prior to
RNA-seq, magnetic beads coated with anti-CD144 antibodies
were added to remove CD144+ hPSC-ECs with a magnetic cell
separator. VSMCs reached 95% purity after purification. Libraries
were prepared with a TruSeq Stranded mRNA Library Prep Kit
and sequenced with Illumina NextSeq 500. Twenty million
75 bp paired-end reads were generated for each sample. The thresholds for differential expression were set at fold-change > 2 and
adjusted p < 0.001 for the null hypothesis. Methods for the data
processing, generation of heatmaps, PCA, and differential gene
expression analysis have been described in our previous publication (Li et al., 2018a).

Statistical Analysis
The data are presented as the mean ± SD from three independent
experiments. We used an unpaired t test to compare two groups
and one-way ANOVA to compare more than two groups. A sample
size of 3 was selected so that at a significance level of 0.05 there was
at least a 95% chance of detecting a 2 SD difference in outcome between the groups. All data were processed using GraphPad Prism 7
(GraphPad Software, La Jolla, CA).
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